玉屏风散加减辅助治疗过敏性鼻炎的系统评价

Modified Yupingfeng Powder in Adjuvant Therapy of Allergic Rhinitis:A Systematic Review

目的:系统评价玉屏风散加减辅助治疗过敏性鼻炎的疗效和安全性,为临床提供循证参考。方法:计算机检索万方数据库、中文科技期刊数据库、中国期刊全文数据库、中国生物医学文献数据库、Cochrane图书馆、EMBase、Pub Med,收集玉屏风散加减联合化学药(试验组)对比单纯化学药(对照组)治疗过敏性鼻炎的随机对照试验,提取资料并按照Cochrane系统评价员手册5.1.0评价纳入研究质量,采用Rev Man 5.2统计软件进行Meta分析。结果:共纳入15项RCT,合计1 366例患者。Meta分析结果显示,试验组患者总有效率[OR=3.95,95%CI(2.80,5.58),P<0.001]显著高于对照组,复发率[OR=0.37,95%CI(0.22,0.63),P<0.001]和不良反应发生率[OR=0.15,95%CI(0.06,0.35),P<0.001]显著低于对照组,差异均有统计学意义。结论:玉屏风散加减辅助治疗过敏性鼻炎疗效较好,可以降低复发率,安全性亦较好。

OBJECTIVE： To systematically evaluate therapeutic efficacy and safety of Yupingfeng powder in adjavant therapy of allergic rhinitis, and to provide evidence-based reference for clinical treatment. METHODS： Retrieved from Wanfang database, VIP, CJFD, CBM, Cochrane Library, EMBase and PubMed, RCTs about Yupingfeng powder combined with chemical medicine （trial group） vs. chemical medicine alone in the treatment of allergic rhinitis were collected. Meta-analysis was conducted by using Rev Man 5.2 statistical software after data extraction and quality evaluation according to Cochrane system evaluation method 5.1.0. RESULTS： A total of 15 RCTs were included, invovling 1 366 patients. The results of Meta analysis showed that response rate [OR=3.95,95%CI（2.80,5.58）,P〈0.001], recurrence rate [OR=0.37,95%CI（0.22,0.63）,P〈0.001] and the incidence of ADR [OR=0.15,95%CI（0.06,0.35）,P〈0.001] in trial group were significantly higher than control group, with statistical significance. CONCLUSIONS： Yupingfeng powder in adjuvant therapy of allergic rhinitis show good therapeutic efficacy and can reduce recurrence rate with good safety.